Product and Services Finder

Categories

Company Address 3300 Duval Rd
Austin, Texas 78759
United States
866 RBM MAPS
512 835 4687 (Fax)

Marketing - General Tiffany Morris
512-835-8026

No Distributors

Myriad RBM, Inc.

Contact Company

Pharmaceuticals Research Library

An Overview of Assay Quality Systems at Rules-Based Medicine
Myriad RBM, Inc.
Stringent guidelines of quality assurance and control (QA/QC) serve as the foundation for dependable and reproducible results in any analytical endeavor. Read step-by-step how the RBM platform combines the sensitivity and dynamic range of microsphere based immuno-multiplexing with the precision and dependability of automated liquid handling.
 
TruCulture Whole Blood Collection and Culture System
Myriad RBM, Inc.
Accurate measurement of immune activity in relation to therapeutic dosing is an important part of many clinical trials, yet is poorly addressed by traditional techniques. Typical immune activity monitoring is performed using isolated leukocytes or even sorted sub- population culturing methods followed by an analytical measurement. These methods require the shipment of intact blood samples to a ...
 
IP-10 MAP 3 Plex
Myriad RBM, Inc.
Myriad RBM’s IP-10 MAP 3-plex is a valuable tool for studying chronic inflammatory diseases. Interferon induced protein 10 (IP-10 or CXCL10) is a chemotactic chemokine that attracts T-lymphocytes, natural killer cells, and monocytes1. The protein exists in multiple forms and in some cases it may antagonize immune system activation depending on its cleavage state. Studies have found IP-10 ...
 
Rat KidneyMAP
Myriad RBM, Inc.
A 12-Biomarker Multi-Analyte Profile (MAP) for Detecting Kidney Toxicity in Rat Preclinical Drug Studies. Sherry Sours-Brothers, Ph.D. and Dominic Eisinger, Ph.D. Introduction Rat KidneyMAP® and Biomarker Qualification by the Predictive Safety Testing Consortium Drug induced toxicity is responsible for killing 30% of promising compounds from early preclinical studies and can negatively impact ...
 
Minimizing Rheumatoid Factor Interference in Myriad RBM's Biomarker Assays
Myriad RBM, Inc.
MINIMIZING Rheumatoid Factor Interference in Myriad RBM's Biomarker Assays Introduction The reduction or elimination of non-specific sources of interfering signals is a critical component of any clinical study relying on the measurement of biomarkers using immunoassays. Interference often arises from heterophile antibodies – antibodies which are relatively non-specific and exhibit broad ...
 

Pharmaceuticals Marketing Documents

Multiplex Biomarkers on the Rise
 
Novel Biomarkers of Cisplatin-induced Kidney Damage
 
EDI-Co gut, a human co-culture from intestinal epithelia and whole-blood used as test model to characterize the effects of micro
 
The Clinical Phenotype of Myelofibrosis Encompasses a Chronic Inflammatory State that is Favorably Altered by INCB018424
 
Development of a new 3D-Human Airway Epithelium/ Whole-blood Co-culture Model Combined with Multi-AnalyteProfile (MAP) Analyses
 
EDI-Co Skin 3D-Co-culture model combined with RBM MAP analyses
 
Development and Validation of a Multi-Analyte Profile (MAP) of Putative Biomarkers of Human Kidney Damage
 
VeriPsych Brochure
 
Development of a mulitplex immunoassay biomarker panel for Spinal Muscular Atrophy
 
Novel Biomarkers of Cisplatin-induced Kidney Damage
 
Development and Validation of a Multi-Analyte Profile Test for Broad Applications in Oncology
 
Myriad RBM, Inc. Document
 
Myriad RBM, Inc. Company

Myriad RBM, Inc. News

Myriad RBM, Inc. Information
Myriad RBM, Inc. Company
Copyright © 2013, JAZD Markets, Inc.
Company descriptions and contact information are quoted from the company's website or other promotional information. JAZ'D is not responsible for the accuracy of this information. Unless specifically noted, JAZ'D is not sponsored by, affiliated with or otherwise connected with any of the listed companies.